Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEF-PHN1
2020-004639-26Phase 2Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postherpetic neuralgia (PHN) comparing LX9211 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 6 in Average Daily Pain Score. Started Feb 2021; status: completed.
02
Drugs
pilavapadin
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on 2020-004639-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004639-26.